About Arthur Winer, MD
Dr. Arthur Winer is a specialty care physician board certified in internal medicine and board eligible in hematology/oncology. He joined Inova Health System in 2020 and has been practicing since 2013.
Prior to joining Inova, Dr. Winer attended New York University School of Medicine where he graduated from medical school and completed his training in internal medicine. He also completed an additional year as an internal medicine chief resident. Most recently, he trained as a hematology/oncology fellow at Temple University Hospital/Fox Chase Cancer Center in Philadelphia, PA.
- American Society of Clinical Oncology
- National Comprehensive Cancer Network
- Pennsylvania Medical Society
Winer A, Denlinger C, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang E, Kunkel M, Lim B, Harvey H, Sivik J, Korzekwa K, Ruth K, White K, Cooper H, Ross E, Zhou L, El-Diery W. First-in-Human Phase Ib Trial of Quinacrine plus Capecitabine in Patients with Refractory Metastatic Colorectal Cancer. Accepted to Clinical Colorectal Cancer. 2020.
Winer A, Bains A. Autoimmune Panmyelosis with Myelofibrosis, Blood. 2019 Oct 10;134(15):1269.
Winer A, Ghalatlia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Diery, W. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist. 2019 Aug 24;8:1-4.
El-Diery W, Winer A, Slifker M, Taylor S, Adamson B, Meropol N, Ross E. Disease control with FOLFIRI plus ziv-aflibercept (zFOLFIRI) beyond FOLFIRI plus bevacizumab: Case series in metastatic colorectal cancer (mCRC). Front Oncol. 2019 Mar 14;9:142.
Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski L, Slifker M, Saltzberg P, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry W. Clinical use of liquid biopsies (LB) to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer (mCRC) patients (pts) at a Fox Chase Cancer Center GI Oncology subspecialty clinic. Front Oncol. 2019 Jan 17;8:652.
Winer A, Bains A. Cryoglobulin-induced red blood cell morphologic changes. Blood. 2018 Jun 28;131(26):2994.
Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018 Jun;17(6):1147-1155.
Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018 Feb;10(Suppl 3):S480-S489.
Winer A, Janosky M, Harrison B, Zhong J, Moussai D, Siyah P, Schatz-Siemers N, Zheng J, Adams S, Mignatti P. Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-Of-Principle Study. Mol Cancer Ther. 2016 Oct;15(10):2370-2377.
Janosky M, Sabado R, Cruz C, Vengco I, Hasan F, Winer A, Moy L, Adams S. MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. Journal for ImmunoTherapy of Cancer, 2(32); 2014.
Medical EducationNew York University School of Medicine 2013
Training Specialty: Internal Medicine
07/01/2013 - 06/30/2017
Training Specialty: Oncology and Hematology
7/1/2017 - 06/30/2020